Hims & Hers inks deal with Eli Lilly to offer branded weight loss drugs
Hims & Hers has signed a partnership agreement with pharmaceutical giant Eli Lilly to offer branded weight loss drugs directly through its platform. The collaboration aims to expand patient access to approved obesity treatments across the United States. While the deal expands product availability, the announcement arrives alongside financial pressures for the telehealth provider. Hims & Hers recently reported a share price surge following the news, though the company also faced an earlier investor selloff linked to shrinking margins, a subscriber slip, and a reduced profit outlook.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Hims & Hers inked a deal with Eli Lilly to offer branded weight loss drugs.
- ✓ Lilly will sell obesity drugs directly on the Hims & Hers site.
- ✓ The partnership expands access to FDA-approved Lilly medicines.
- ✓ The collaboration is designed to reach more weight-loss drug patients and boost access to obesity drugs in the United States.
What changed
Hims & Hers officially secured a direct-to-consumer agreement with Eli Lilly to distribute branded weight loss medications.
Live updates
-
Hims & Hers Inks Deal With Eli Lilly
Hims & Hers has signed a partnership agreement with pharmaceutical giant Eli Lilly to offer branded weight loss drugs directly through its platform. The collaboration aims to expand patient access to approved obesity treatments across the United States. While the deal expands product availability, the announcement arrives alongside financial pressures for the telehealth provider. Hims & Hers recently reported a share price surge following the news, though the company also faced an earlier investor selloff linked to shrinking margins, a subscriber slip, and a reduced profit outlook.
Why it matters
The agreement aligns a major telehealth platform with a leading manufacturer of popular obesity medications amid surging consumer demand for weight loss therapies. Expanding distribution channels allows pharmaceutical companies to reach wider patient populations online. For digital health platforms, offering high-demand branded drugs marks a strategic shift toward established treatments alongside compounded alternatives.
What is confirmed
- Hims & Hers inked a deal with Eli Lilly to offer branded weight loss drugs.
- Lilly will sell obesity drugs directly on the Hims & Hers site.
- The partnership expands access to FDA-approved Lilly medicines.
- The collaboration is designed to reach more weight-loss drug patients and boost access to obesity drugs in the United States.
Still unconfirmed
- Hims & Hers stock surged on what investors viewed as a surprising and inevitable deal with Eli Lilly.
- Hims & Hers previously experienced a share price drop due to a Q3 loss and profit outlook cut.
What to watch next
- Implementation timelines for launching branded Eli Lilly drugs on the Hims & Hers platform
- Future financial reports reflecting the impact of the branded drug partnership on subscriber numbers and margins
confidence 100%Sources used for this update (8)
- Investor's Business Daily — Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly
- Reuters — Lilly to sell obesity drugs directly on Hims & Hers site
- PR Newswire — Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
- Bloomberg.com — Lilly, Hims Join Forces to Reach More Weight-Loss Drug Patients
- FirstWord Pharma — Lilly turns to Hims & Hers to boost access to obesity drugs in US
- Fierce Healthcare — Hims & Hers inks deal with Eli Lilly to offer branded weight loss drugs
- Simply Wall St — Is Hims & Hers Health (HIMS) A Bargain After Its Lilly Deal?
- 247wallst.com — Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community